Current Report Filing (8-k)
06 Juin 2023 - 10:23PM
Edgar (US Regulatory)
0000012239
false
0000012239
2023-06-05
2023-06-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or Section 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 5, 2023
Dominari
Holdings Inc.
(Exact name of registrant as specified in its charter)
Delaware |
|
000-05576 |
|
52-0849320 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
725
5th Avenue, 23rd
Floor
New York, NY 10022
(703) 992-9325
(Address, including Zip Code and Telephone
Number, including
Area Code, of Principal Executive Offices)
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, $0.0001 par value |
|
DOMH |
|
The Nasdaq Capital Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As previously reported, effective May 16, 2023, Mr.
Carlos Aldavero (“Mr. Aldavero”) is no longer affiliated with Dominari Holdings Inc. (the “Company”) or Dominari
Financial Inc. (“Dominari Financial”). On June 5, 2023, the Company and Dominari Financial entered into a Settlement and Release
Agreement (the “Settlement Agreement”) with Mr. Aldavero whereby Mr. Aldavero voluntarily resigned from Dominari Financial.
Item 8.01 Other Events.
The Settlement
Agreement referenced in Item 5.02 provides for a one-time payment by the Company to Mr. Aldavero and/or his designees in the total amount
of $225,000.00 on or before June 15, 2023. The Settlement Agreement requires Mr. Aldavero to have the litigation he filed against the
Company dismissed by June 16, 2023, and also provides for his complete release of any and all claims, suits or other actions against
the Company, Dominari Financial, or any of their affiliates or subsidiaries. The Settlement Agreement also contains customary mutual non-disparagement
provisions.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated June 6, 2023 |
DOMINARI HOLDINGS INC. |
|
|
|
|
By: |
/s/ Anthony Hayes |
|
Name: |
Anthony Hayes |
|
Title: |
Chief Executive Officer |
2
Alkido Pharma (NASDAQ:AIKI)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Alkido Pharma (NASDAQ:AIKI)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025